INSTRUCTIONS TO CONTRIBUTORSJapanese Journal of Therapeutic Drug Monitoring(Revised on April 5, 2021)
The Japanese Journal of Therapeutic Drug Monitoring (Jpn J Ther Drug Monit) is devoted
tothepublicationofscientificarticlesconcerning

therapeutic

drug

monitoring,

pharmacodynamics, and pharmacokinetics of drugs in every field of medicine.

The journal

consists of multidisciplinary fields of science: It serves as a forum for exchange of information
among experimental and developmental pharmacologists, clinical pharmacists, medicallaboratory technologists, clinical pharmacologists, medical doctors and related personnel using
drugs for therapy.

Manuscripts on the development, assay methods, mechanism of action,

safety and efficacy, disposition, and interaction of drugs are considered, as well as thoseconcerning adverse effects and toxic reaction of drugs, and the role of factors such as environment,
nutrition, and disease states in modulating the drug processes.
1. Category and language of the manuscript
1-1 Manuscripts categories are original articles, review articles, case reports, shortcommunications, meeting and seminar proceedings, reports on international meetings,
and introductions of laboratory.
1-2 Languages are limited either to Japanese or English.
2. Qualification of manuscript submission
Manuscripts are eligible to be submitted regardless that the authors are the membersof the Japanese Society of Therapeutic Drug Monitoring or not, however, the manuscript
handling fee must be paid according to the process described in 4-5 when the first author of
the manuscript is not the member of the Society.

As for manuscripts submitted as originalarticles, review articles, case reports, and short reports, they must be submitted solely tothis journal, and have not been published in any part or form in another publication except
for meeting abstracts.
3. Copyrights
Copyrights of the published manuscripts in the journal belong to the Japanese Societyof Therapeutic Drug Monitoring.

Upon acceptance of manuscripts for publication, theauthors will be required to sign an agreement transferring copyright to the publisher. No
published material may be reproduced elsewhere without the written permission of theJapanese Society of Therapeutic Drug Monitoring.
4. Submission of the manuscript1

4-1 Manuscripts and all editorial correspondence are, in general, uploaded via themanuscript submission system located at the website of the Japanese Society of
Therapeutic Drug Monitoring (https://mc.manuscriptcentral.com/jjtdm). Authors unable
to use the Japanese website may send manuscripts directly to the Editor-in-Chief asattached files via e-mail (JJTDM@pharm.hokudai.ac.jp).
4-2 Manuscripts on human studies requiring ethical consideration need to be accompanied
by a certificate indicating approval by the ethical committee.

The certificate should

include study title, approval number or equivalent and the date of approval.

The

document can be sent by facsimile when sending a certificate as an electronic file via email is difficult (+81-11-706-4984).

For clinical studies with intervention, briefsummary need to be registered to the specified public database according to the “EthicalGuidelines for Medical and Health Research Involving Human Subjects” released on
December 22, 2014 by the Ministries of Education, Culture, Sports, Science andTechnology, and Health, Labour and Welfare of Japan.

Studies that involve animalexperiments, should be performed with an appropriate experimental design thatprevents cruelty to animals.
4-3 As for manuscripts submitted as original articles, review articles, case reports, and shortreports, every author must confirm his/her own status of the conflict of interest (COI)
using the COI self-checklist (Form 2) defined in the COI-Management Rules, theJapanese Society of Therapeutic Drug Monitoring, and COI-status must be disclosed justbefore References section.
4-4 Authors whose "first" language is not English are encouraged to have their manuscript
edited by a native English speaker, and upload a certificate provided by the person.

The

document can be sent by facsimile when sending a certificate as an electronic file via email is difficult (+81-11-706-4984).
4-5 When the first author of the manuscript is not the member of the Japanese Society of
the Therapeutic Drug Monitoring, the manuscript handling fee (¥8,000) must betransferred to the following bank account of the Japanese Society of the Therapeutic
Drug Monitoring immediately after completion of manuscript submission andacquisition of the temporary manuscript reception number (Bank name: Kyoto bank,Branch name: yamashinashiten, Account number: 4186886, Account holder: ippan
syadan houjin nihon TDM gakkai daihyouriji sakaeda toshiyuki).

The authors are also

required to notify 1) corresponding author’s name, 2) manuscript reception number, 3)affiliation of the corresponding author, 4) sender’s name of the manuscript handling fee,5) transfer date, to the Society office (office@jstdm.jp) as well as Editor-in-Chief(JJTDM@pharm.hokudai.ac.jp) by E-mail.

The fee will not be reimbursed whatever thereason after reception of the manuscript.
4-6 Please include following items in the cover letter, and then upload through the2manuscript submission system.

1) The manuscript is original and is not underconsideration by other journals, and has not been published elsewhere. 2) All authors
have contributed to either research design, performance, analyses of the study or writingof the manuscript, and have agreed to submit the manuscript.

3) Ethical considerationof the study, if necessary.
5. Reviewing and publishing processes
5-1 Reviewing of the manuscript will be started on the date of receipt when the above
mentioned processes are finished.
5-2 Decision on the manuscript will be made by the Editor-in-Chief based on the comments
made by at least two peer reviewers.
5-3 Authors must submit a revised manuscript with itemized responses to the reviewers’comments through the electronic submission site within 2 months when revision isrequired.
5-4 If the fact is uncovered that the manuscript is fabricated or appropriated, or themanuscript is submitted by duplicate, the manuscripts will be rejected when the statusof the manuscript is before editorial decision. The manuscript may be withdrawn evenafter the acceptance of the manuscript for publication.
5-5 The accepted article will be published in the order of acceptance.
6. Organization of the manuscript
6-1 LENGTH AND MARGINS: The length of the printed article is limited to 6 or fewer pages
for original articles, 8 or fewer pages for review articles, and 3 or fewer pages for casereports and short communications.

The manuscript should be formatted double space

A4 page size with approximately 2.5 cm margins on every side.

Each figure or table

will be regarded as approximately 250 words.
6-2 ABBREVIATIONS AND SYMBOLS:

Times font should be used for the text and Arial

font should be used for the title and headlines with 12 point size. Use Roman figure forthe numerals of headlines. All uncommon abbreviations and symbols must be defined
at first mention in the text.
6-3 WEIGHTS AND MEASURES: All weights and measures should be in metric units.

Use

Arabic numerals for any numeral expressions.
6-4 STRUCTURES: Include the following sections in original articles and case reports.
Sections may be combined when necessary.

Begin each section on a separate page.

Insert page numbers at the bottom center starting from the title page.
1) Original article: Title page, Abstract, Introduction, Materials and Methods, Subjects,Results, Discussion, Conflict of Interest, References
2) Case report: Title page, Abstract, Introduction, Case, Discussion, Conflict of Interest,3

References
6-5 TITLE PAGE: Title page should contain an informative title, the names and affiliationsof all authors (indicate their affiliations with Arabic numerals when there are two ormore). The corresponding author must be indicated with an asterisk as a superscript.
The name, physical address, e-mail address, telephone number, and facsimile number
for the corresponding author must be included.
6-6 ABSTRACT: Abstract should summarize the study and include a statement of theproblem, methods, results, and conclusions.

Abstract should not exceed 250 words.

6-7 KEYWORDS: Supply a list of three to six key words or short phrases that will adequately
index the subject matter of the article after ABSTRACT.
6-8 FIGURES AND TABLES:
1) Provide only indispensable figures and tables for explanation of the study results.
Each page will contain one figure or table.
2) Figures and tables should be numbered in respective consecutive order of appearance
using Arabic numerals and be keyed into the text.
3) Figures and tables should be made in black and white as a rule. When necessary,
they may be made in a color; however, the cost for color page printing will be charged
to the authors.
4) Figures and tables must be of good quality.

Figures and tables will be reproduced

reducing the size to fit one column (8 cm) or two columns (16 cm) for printing.
5) A descriptive legend must accompany each figure or table so that it can be understoodapart from the text.
page from figures.

Titles and legends for figures should be written on a separate
Titles and legends for tables must be provided in the tables.

6-9 REFERENCES:
1) Cite 25 or fewer references for an original article and a case report, 50 or fewer
references for a review article, which are relevant to the article. References must be
numbered consecutively in the order in which they are first mentioned in the text as
superscript numerals. Internet addresses including the date of access, abstracts ofmeetings, official documents should be listed in the REFERENCES section but not inthe text.
2) Each reference should be written as follows.
- List all authors if there are 6 or fewer authors, however, list the first 3 authors
followed by et al. if there are 7 or more authors.
- Abbreviate journal names according to PubMed.
- Refer to the sample references according to the International Committee of Medical
Journal Editors (ICMJE) Uniform Requirements for Manuscripts Submitted toBiomedical Journals listed at the following address (http://www.nlm.nih.gov/bsd/uniform_ requirements.html), when necessary.
4

- Journal Articles: Authors names. Title. Journal name. Publication year; Volume: First
page-Last page.
Ex) Tanigawara Y, Nozawa K, Tsuda H. Optimal dose finding of garenoxacin based on
population pharmacokinetics/pharmacodynamics and Monte Carlo simulation.
Eur J Clin Pharmacol 2012; 68: 39-53.
- Books: Authors names. Book title. Edition number. City of publication: Publisher's
name; Year of publication.
Ex) Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and applications, 3rded. Philadelphia: Williams & Wilkins; 1995.
- Chapter in Book: Authors names. Chapter title. In: Editors’ name (if any). Book title.
Edition number. City of publication: Publisher's name; Year of publication. p. First
page cited-Last page cited.
Ex) Dowling TC. Quantification of renal function. In: Dipiro JT, Talbert RL, Yee GC,Matzke GR, Wells BG, Posey LM eds. Pharmacotherapy: A pathophysiologicapproach, 7th ed. New York: McGraw Hill; 2008. p. 705-722.
- Internet: Person or Organization. City of publication: Title. (internet address) Year ofpublication (Date of access)Ex) Food and Drug Administration. Silver Spring: Guidance for Industry Drug
Interaction Studies - Study Design, Data Analysis, Implications for Dosing, andLabeling Recommendations DRAFT GUIDANCE. (www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf)
2012 (Accessed on September 1, 2012).
7. Reprint order and author proof
Reprint order forms will be sent with the proofs.

Authors have only one opportunity ofproof correction.
8. Inquiry about editing:
Mitsuru SUGAWARA, Ph.D.
Editor-in-Chief, Japanese Journal of Therapeutic Drug Monitoring
c/o Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido
University
Kita 12, Nishi 6, Kita-ku, Sapporo, Hokkaido 060-0812 Japan
E-mail：JJTDM@pharm.hokudai.ac.jp

5